BCL2L1 and adenoma: After 3 weeks, all of the ABT-199 treated mice had discernable adenomas while only one of five A-1155463 treated mice presented with a small adenoma (Fig. 4a, b), thus confirming that BCL-XL inhibition effectively attenuates adenoma outgrowth in vivo.